DDIT3 and diffuse large B-cell lymphoma: Rituximab with dose‐reduced CHOP (R‐miniCHOP)9 and ofatumumab (anti‐CD20)‐miniCHOP10 in patients older than 80 years with DLBCL and who have a good performance status improved tolerability and provided an effective treatment option, albeit with response and survival rates lower than in younger patients with DLBCL.